Compare · EWTX vs PEPG
EWTX vs PEPG
Side-by-side comparison of Edgewise Therapeutics Inc. (EWTX) and PepGen Inc. (PEPG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EWTX and PEPG operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- EWTX is the larger of the two at $4.51B, about 12.2x PEPG ($370.4M).
- Both names hit the wire about 12 times in the past 4 weeks.
- EWTX has more recent analyst coverage (17 ratings vs 6 for PEPG).
- Company
- Edgewise Therapeutics Inc.
- PepGen Inc.
- Price
- -
- -
- Market cap
- $4.51B
- $370.4M
- 1M return
- -
- +39.26%
- 1Y return
- -
- -26.27%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2022
- News (4w)
- 12
- 12
- Recent ratings
- 17
- 6
Edgewise Therapeutics Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Latest EWTX
- CMO Joanne M. Donovan sold $38,840 worth of shares (854 units at $45.48), decreasing direct ownership by 9% to 8,139 units (SEC Form 4)
- SEC Form 144 filed by Edgewise Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Edgewise Therapeutics Inc.
- Chief Financial Officer Nofi Michael converted options into 10,937 shares and sold $201,787 worth of shares (4,442 units at $45.43) (SEC Form 4) to cover withholding tax
- /C O R R E C T I O N - Edgewise Therapeutics/
- Edgewise Therapeutics to Participate in Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Edgewise Therapeutics Inc.
- Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
- SEC Form 10-Q filed by Edgewise Therapeutics Inc.
- Edgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest PEPG
- Amendment: SEC Form SCHEDULE 13D/A filed by PepGen Inc.
- Director Ra Capital Management, L.P. bought $43,125,000 worth of shares (8,625,000 units at $5.00) (SEC Form 4)
- PepGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by PepGen Inc.
- PepGen Announces Pricing of $125 Million Public Offering
- SEC Form 424B5 filed by PepGen Inc.
- PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
- PepGen upgraded by BofA Securities with a new price target
- PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by PepGen Inc.